Reducing Product Costs
First written in FY2016-Q3. 4 of 10 entries say "Restated". Latest entry: FY2023.
ImageONE moved to the "Worse" side of this theme in 2024, 2 years before the typical company in this theme (2026).
The whole theme swung hardest in 2021: 2 of 8 companies on the "Worse" side.
2 other companies' latest entry also says "Worsened".
- FY2023WorsenedAnnual report
「Meanwhile, selling, general and administrative expenses increased because of higher sales costs and higher sales administration costs, among other factors. As a result, the Company was unable to secure operating profit and recorded an operating loss.」
While the policy of improving margins through reductions in product costs and other costs continued, higher sales and sales administration costs resulted in an operating loss of ¥685.047 million. - FY2021Cost burden from low-margin large projectsAnnual report
「Several large, low-margin projects arose. Although orders for i-HIS, a cloud-based electronic medical records system, were trending higher than in the previous fiscal year, the segment reported a loss mainly because costs increased as the period from order receipt to completion of installation was prolonged.」
Despite efforts to reduce costs and improve margins, low-margin large projects and higher costs resulting from the prolonged installation period for i-HIS weighed on profit. - FY2018AdvancedAnnual report
「Together with the benefits of ongoing efforts to improve the efficiency of system implementation processes, substantial earnings improvement progressed.」
The annual results showed that ongoing efforts to improve the efficiency of system implementation processes contributed to earnings improvement, including operating profit of ¥220 million in the Healthcare Solutions business. - FY2018-Q3AdvancedAnnual report
「For the nine-month period ended 31 December, the Healthcare Solutions Business posted net sales of ¥852 million, up 16.3% year on year, and operating income of ¥101 million, up 930.1%. Although price competition for medical imaging system products continues to intensify, sales grew as the benefits of collaboration with modality manufacturers and medical information system manufacturers, initiatives pursued since the previous fiscal year, began to emerge. Together with the effects of streamlining system implementation processes, this led to substantial earnings improvement.」
The Company explained that ongoing efforts to improve the efficiency of system implementation processes, together with the benefits of collaboration, led to substantial earnings improvement, including operating profit of ¥101 million. - FY2018-Q2AdvancedAnnual report
「Although price competition for medical imaging system products continued to intensify, sales grew as the benefits of collaboration with modality manufacturers, an initiative undertaken since the previous fiscal year, began to emerge. Together with the benefits of efforts to improve the efficiency of system implementation processes, this led to substantial earnings improvement.」
The Company explained that the benefits of its ongoing efforts to improve the efficiency of system implementation processes contributed to earnings improvement. - FY2017-Q3RestatedAnnual report
「Across the medical imaging business, the Company continued cost-reduction measures, including reviewing the composition of procured products, an initiative undertaken since the previous fiscal year, while working to improve the efficiency of system implementation processes.」
The Company continued cost reductions, including through a review of the composition of procured products, and improved the efficiency of system implementation processes. - FY2017-Q2RestatedAnnual report
「Across the medical imaging business, the Company continued cost-reduction measures, including reviewing the composition of procured products, an initiative undertaken since the previous fiscal year, while working to improve the efficiency of system implementation processes.」
The Company continued cost reductions, including through a review of the composition of procured products, and improved the efficiency of system implementation processes. - FY2017-Q1RestatedAnnual report
「Across the medical imaging business, the Company continued cost-reduction measures, including reviewing the composition of procured products, an initiative undertaken since the previous fiscal year, while working to improve the efficiency of system implementation processes.」
The Company continued cost reductions, including through a review of the composition of procured products, and improved the efficiency of system implementation processes. - FY2016RestatedAnnual report
「Following the operating loss recorded for the fiscal year ended September 2015, the Company focused on reducing costs by reviewing the entire procurement process.」
The policy of reviewing the entire procurement process to reduce costs continued to be reported in the annual report. - FY2016-Q3First statedAnnual report
「The Company designated reduction of product costs as one of three priority measures for the current fiscal year and developed its business accordingly. In the medical imaging business, it reviewed operations throughout the procurement process and worked to reduce costs, as well as」
The Company reviewed the entire procurement process and proceeded with cost reductions.